Journal article

A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer

Shane Stegeman, Ernest Amankwah, Kerenaftali Klein, Tracy A O'Mara, Donghwa Kim, Hui-Yi Lin, Jennifer Permuth-Wey, Thomas A Sellers, Srilakshmi Srinivasan, Rosalind Eeles, Doug Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch, Kenneth Muir, Graham G Giles, Fredrik Wiklund, Henrik Gronberg, Christopher A Haiman, Johanna Schleutker Show all

Cancer Discovery | AMER ASSOC CANCER RESEARCH | Published : 2015

Grants

Awarded by Cure Cancer Australia Foundation and Cancer Australia PdCCRS


Awarded by NHMRC


Awarded by Department of Defense


Awarded by NCI


Awarded by Cancer Prevention Fellowship from the NCI


Awarded by European Commission's Seventh Framework Programme


Awarded by Cancer Research UK (CRUK)


Awarded by NIH Cancer PostCancer GWAS initiative grant


Awarded by Post-Cancer GWAS initiative


Awarded by Cancer Research UK


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Funding Acknowledgements

J. Batra was supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship. A.B. Spurdle is an NHMRC Senior Research Fellow. J.A. Clements is an NHMRC Principal Research Fellow. This work was supported by Cure Cancer Australia Foundation and Cancer Australia PdCCRS grant 1068321 and NHMRC grant 1050742 (Principal Investigator, J. Batra); Department of Defense grant W81XWH-12-1-0113 (Principal Investigator, J.Y. Park); and NCI R01CA128813 (Principal Investigator, J.Y. Park). E.K. Amankwah was supported by a Cancer Prevention Fellowship from the NCI (R25T CA147832) while this study was conducted. The Australian Prostate Cancer BioResource (APCB) funding was obtained from the NHMRC (enabling grant 614296) and an infrastructure grant from the Prostate Cancer Foundation of Australia.This work was supported by the Canadian Institutes of Health Research; European Commission's Seventh Framework Programme grant agreement no223175 (HEALTH-F2-2009-223175); Cancer Research UK (CRUK) grants C5047/A7357, C1287/A10118, C5047/A3354, C5047/A10692, and C16913/A6135; and NIH Cancer PostCancer GWAS initiative grant no. 1 U19 CA 148537-01 (the GAME-ON initiative). The authors acknowledge support from the NIHR to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust.Funding for the iCOGS infrastructure came from the European Commission's Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175); Cancer Research UK grants C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, and C5047/A10692; NIH CA128978; and the Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065, and 1U19 CA148112--the GAME-ON initiative). This study was also supported by the Department of Defense (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.